Shares of ImmunityBio, Inc. (NASDAQ: IBRX) surged over 34% on Thursday, October 25, 2024, as the immunotherapy developer announced the initiation of dosing in a Phase 1 clinical trial for its novel CD19 t-haNK cell therapy.
The Phase 1 trial aims to evaluate the safety and preliminary efficacy of ImmunityBio's CD19 t-haNK cell therapy in patients with relapsed or refractory B-cell malignancies. This investigational therapy combines the company's proprietary natural killer (NK) cell platform with a chimeric antigen receptor (CAR) targeting the CD19 antigen, which is commonly expressed in various B-cell cancers.
The positive development concerning ImmunityBio's cancer treatment pipeline appears to be driving the significant stock price increase, as investors anticipate the potential success of the company's innovative immunotherapy approach. The company's focus on developing cutting-edge cellular therapies for various cancers has garnered significant interest from the biotech investment community.